Longitudinal tau imaging in individual patients with clinical CBS has shown an increase in tracer binding with disease progression [69, 90], while tracer binding in PSP patients correlates well with clinical scores of functional impairment [86, 91], although the latter finding has so far not been replicated in other, larger patient samples with [18F]AV1451 [81, 83]. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.